Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53, STAG2, and CDKN2A Alterations.

Lieke Mous, Stelly Ballet, Sylvain Dureau, Camille Benoist, Eleonore Frouin, Victor Renault, Laura Kirton, Peter Peneder, Nina Jehanno, Anja L Frei, Stéphanie Reynaud, Eve Lapouble, Anne-Sophie Plissonnier, Marie-Emmanuelle Legrier, Ellen Blanc, Aurélie Guinot, Jennifer Anderton, Piers Gaunt, Abigail Evans, Sandra J Strauss, Manuela Krumbholz, Markus Metzler, Elizabeth A Roundhill, Susan A Burchill, Samuel Abbou, Sarah Winter, Martin G McCabe, Nathalie Gaspar, Birgit Geoerger, Gudrun Schleiermacher, Eleni M Tomazou, Nadège Corradini, Valerie Laurence, Bernadette Brennan, Perrine Marec-Berard, Olivier Delattre, Gaelle Pierron, Didier Surdez

DOI: 10.1200/jco-26-00280

На странице источника доступны аннотация, полный текст или сведения о том, где его прочитать.